Oct 10, 2022 01:25AM
Oct 3, 2022 08:33AM
Oct 3, 2022 08:30AM
Sep 15, 2022 01:25AM
Aug 12, 2022 08:33AM
Aug 12, 2022 08:30AM
Jul 28, 2022 08:30AM Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs
Jun 8, 2022 01:25AM
May 31, 2022 01:30AM
May 26, 2022 07:20AM
May 23, 2022 01:20AM
May 23, 2022 01:20AM
May 9, 2022 02:05AM
May 6, 2022 08:30AM Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference
Apr 27, 2022 01:25AM
Apr 26, 2022 01:25AM
Apr 22, 2022 01:25AM
Apr 12, 2022 08:30AM
Apr 12, 2022 01:20AM
Apr 1, 2022 01:40AM
Apr 1, 2022 01:30AM Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized Aviptadil in Critically Ill Patients with COVID-19
Mar 31, 2022 01:30AM
Mar 28, 2022 01:30AM
Mar 21, 2022 02:30AM
Feb 1, 2022 01:25AM
Jan 27, 2022 08:30AM
Oct 7, 2021 08:33AM
Oct 7, 2021 08:30AM Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Formulation
Oct 6, 2021 08:31AM
Oct 6, 2021 08:30AM

15,434 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All